Department of Internal Medicine, Dijon Bourgogne University Hospital, Dijon, France.
Department of Ophthalmology, Dijon Bourgogne University Hospital, Dijon, France.
Ocul Immunol Inflamm. 2020;28(2):281-284. doi: 10.1080/09273948.2018.1545914. Epub 2018 Nov 20.
: To discuss the use of tocilizumab in mild to severe Graves' ophthalmopathy as corticosteroid-adjunctive therapy. : Retrospective case reports.: Three patients with corticosteroid-resistant or advanced diplopia-associated Graves' ophthalmopathy were subsequently treated with monthly intravenous tocilizumab at a dose of 8 mg/kg. None reported a past or present history of dysthyroidism. The adjunction of interleukin-6-receptor monoclonal antibody treatment was associated with a significant improvement in ocular symptoms, notably diplopia and proptosis, and functional prognosis in all patients, with one relapse approximately two months after the end of the treatment.: These clinical reports confirm the relative efficacy and tolerability profile of intravenous tocilizumab in severe or corticosteroid-resistant Graves' ophthalmopathy.
探讨托珠单抗在轻至重度格雷夫斯眼病中作为皮质类固醇辅助治疗的应用。
回顾性病例报告。
3 例皮质类固醇耐药或伴有进展性复视的格雷夫斯眼病患者随后每月接受 8mg/kg 的静脉注射托珠单抗治疗。无患者报告有既往或现患甲状腺功能亢进症病史。白细胞介素-6 受体单克隆抗体治疗的辅助应用与所有患者的眼部症状（特别是复视和眼球突出）和功能预后显著改善相关，1 例患者在治疗结束后大约两个月出现 1 次复发。
这些临床报告证实了静脉注射托珠单抗在严重或皮质类固醇耐药性格雷夫斯眼病中的相对疗效和耐受性。
